Drug Profile
UBX 0101
Alternative Names: UBX0101Latest Information Update: 30 Nov 2020
Price :
$50
*
At a glance
- Originator UNITY Biotechnology
- Class Anti-inflammatories; Antirheumatics; Small molecules
- Mechanism of Action Proto-oncogene protein c mdm2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Osteoarthritis
Most Recent Events
- 17 Nov 2020 UNITY Biotechnology discontinues a long-term follow-up trial for Osteoarthritis in USA (NCT04349956)
- 18 Sep 2020 Unity Biotechnology completes a phase I trial for Osteoarthritis in USA (NCT04229225)
- 17 Aug 2020 Safety and efficacy data from a phase II trial in Osteoarthritis released by UNITY Biotechnology